Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Interest & Investment Income (2020 - 2024)

Immuneering (IMRX) has 5 years of Interest & Investment Income data on record, last reported at $415240.0 in Q4 2024.

  • For Q4 2024, Interest & Investment Income fell 44.94% year-over-year to $415240.0; the TTM value through Dec 2024 reached $2.6 million, down 28.1%, while the annual FY2024 figure was $2.6 million, 28.1% down from the prior year.
  • Interest & Investment Income reached $415240.0 in Q4 2024 per IMRX's latest filing, down from $547072.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.2 million in Q2 2023 and bottomed at $518.0 in Q4 2020.
  • Average Interest & Investment Income over 5 years is $410351.1, with a median of $319112.0 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 27483.98% in 2021, then crashed 44.94% in 2024.
  • A 5-year view of Interest & Investment Income shows it stood at $518.0 in 2020, then surged by 27483.98% to $142885.0 in 2021, then surged by 261.25% to $516168.0 in 2022, then skyrocketed by 46.1% to $754143.0 in 2023, then plummeted by 44.94% to $415240.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $415240.0 in Q4 2024, $547072.0 in Q3 2024, and $826104.0 in Q2 2024.